BPG is committed to discovery and dissemination of knowledge
JOURNAL HOME
Number of total visits
33519937
Number of visits today
2492
Number of downloads
16706310
MEMBERSHIP
BPG JOURNALS
Cited by in F6Publishing
For: Crotty GF, Lo RY, Schwarzschild MA. If LRRK2 Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames? Mov Disord 2020;35:1727-30. [PMID: 33068466 DOI: 10.1002/mds.28240] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 Alrouji M, Al-Kuraishy HM, Al-Gareeb AI, Saad HM, Batiha GE. A story of the potential effect of non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson's disease: beneficial or detrimental effects. Inflammopharmacology 2023. [PMID: 36961665 DOI: 10.1007/s10787-023-01192-2] [Reference Citation Analysis]
2 Menozzi E, Schapira AHV, Blandini F, Avenali M. Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach. Curr Neurol Neurosci Rep 2023. [PMID: 36881256 DOI: 10.1007/s11910-023-01259-1] [Reference Citation Analysis]
3 Sun X, Xue L, Wang Z, Xie A. Update to the Treatment of Parkinson's Disease Based on the Gut-Brain Axis Mechanism. Front Neurosci 2022;16:878239. [PMID: 35873830 DOI: 10.3389/fnins.2022.878239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Aasly JO. Inflammatory Diseases Among Norwegian LRRK2 Mutation Carriers. A 15-Years Follow-Up of a Cohort. Front Neurosci 2021;15:634666. [PMID: 33584195 DOI: 10.3389/fnins.2021.634666] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Write to the Help Desk
© 2004-2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345